Kymos opens new biotechnology R&D area in Barcelona Science Park
The Catalan CRO will present their services for the development of innovative biological products, biosimilars and vaccines at BIO Boston, from 18 to 21 June.
By Biocat
CRO (Contract Research Organization) Kymos Pharma Services has started up a new immunology laboratory in the Barcelona Science Park (PCB), which has successfully passed audits following the Laboratory Best Practices (LBP). Kymos already has three other laboratories in the PCB for bioanalysis, analytic development and quality control. This project has been made possible thanks to their agreement with multinational biotechnology firm Ipsen, in December 2011, allowing Kymos to take on the team of scientists, equipment and know-how of Ipsen’s former R&D headquarters in Spain.
The new biotechnology division will focus on offering services for the development of innovative biological projects, biosimilars and vaccines. The heads of this Catalan CRO will present the new R&D area at the top global biotechnology convention, BIO, which will take place 18 to 21 June in Boston (Massachusetts, United States). A Catalan delegation of 72 companies and organizations will travel to the event coordinated by Biocat.
"Although we have only recently initiated this activity, the perspectives are very good. We have already awoken the interest of important pharmaceutical companies both in this country and abroad, and have signed our first contracts,” explained Joan Puig de Dou, strategic general manager of Kymos.
The company, with 45 professionals on staff, expects to reach a turnover of €4 million in 2012.
More information is available on the PCB website.
